Skip to Content

Dermaxon Logo Dermaxon

Further exploring the brain-skin connection for a better life

DermaXon: DermaXon is a Montana-based drug discovery company founded in 2013 providing first in-class drug candidates.

DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin cornification. The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. This polypharmacological approaches aim to understand and optimize the unknown off-targets activities for existing small molecules such as cannabinoids or retinoic acid. DermaXon uses medicinal chemistry, molecular biology and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by small molecules.

Learn More

Our Technologies

DermaXon was founded in 2013. We provide formulated first-in-class molecules across the following therapeutic areas: Alzheimer’s disease, Parkinson’s disease, Skin conditions and Pain.

LEARN MORE

Pathologies

Dermaxon provides formulated first-in-class molecules across the following therapeutic areas:
  • Ichthyosis
  • Pain
  • Acne

News

Recent conferences we attended where we either had a presentation or posters

The 12th Annual Pain and Migraine Therapeutics Summit –... Read More

June 2018

DermaXon received a Phase 1 STTR Grant funding from the National... Read More

May 2018

DermaXon presented at the 2018 Society for Investigative Dermatology... Read More

April 2017

DermaXon won the “Shark Tank” pitching competition... Read More

^ Back to Top
MENU